PEAK6
ALNY icon

PEAK6’s Alnylam Pharmaceuticals ALNY Stock Holding History

PEAK6’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,600
Closed -$3.18M – 2689
2026
Q1 		$3.18M Buy
+9,600
New +$3.27M 0.01% 1121
2025
Q4 		– Sell
-700
Closed -$319K – 2790
2025
Q3 		$319K Sell
700
-600
-46% -$244K ﹤0.01% 2313
2025
Q2 		$424K Sell
1,300
-12,000
-90% -$3.32M ﹤0.01% 2191
2025
Q1 		$3.59M Sell
13,300
-34,400
-72% -$8.84M 0.01% 1104
2024
Q4 		$11.2M Buy
+47,700
New +$12.5M 0.02% 525

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PEAK6's ALNY Position: Q2 2026 in Review

PEAK6 reduced its Alnylam Pharmaceuticals (ALNY) stake by 36% in Q2 2026, selling an estimated $1.05M and leaving 6,231 shares worth $1.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

PEAK6 first reported a position in ALNY in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.21M in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • PEAK6 held 6,231 shares of Alnylam Pharmaceuticals worth $1.88M as of Q2 2026.
  • PEAK6 sold 3,485 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.05M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of PEAK6's portfolio in Q2 2026, its #1361 holding.
  • PEAK6 first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • PEAK6's Alnylam Pharmaceuticals position peaked at $3.21M in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.